- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Non-small cell lung cancer (NSCLC)
- Meeting Date: November 2025
- Public Summary Document (PSD) November 2025 PBAC Meeting - (PDF 1.3MB)
- Public Summary Document (PSD) November 2025 PBAC Meeting - (Word 740.7KB)
Encorafenib and binimetinib – November 2025
Encorafenib and binimetinib: Capsule 75 mg Tablet 15 mg Tablet 45 mg; Braftovi® Mektovi® - November 2025
Last updated
5 November 2025